About Aeolus Pharmaceuticals (OTCMKTS:AOLS)
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
Industry, Sector and Symbol
Industry Drug Manufacturers - Other
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$2.08 million
Price / Sales3.22
Price / CashN/A
Book Value$0.02 per share
Price / Book2.20
Return on Equity-246.63%
Return on Assets-175.14%
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions
What is Aeolus Pharmaceuticals' stock symbol?
Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."
How were Aeolus Pharmaceuticals' earnings last quarter?
Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. Aeolus Pharmaceuticals had a negative return on equity of 246.63% and a negative net margin of 531.00%. View Aeolus Pharmaceuticals' Earnings History.
Who are some of Aeolus Pharmaceuticals' key competitors?
Some companies that are related to Aeolus Pharmaceuticals include OHR Pharmaceutical (OHRP), Acura Pharmaceuticals (ACUR), Check Cap (CHEK), Heat Biologics (HTBX), Jaguar Health (JAGX), Windtree Therapeutics (WINT), Cytori Therapeutics (CYTX), Eyegate Pharmaceuticals (EYEG), OpGen (OPGN), Critical Outcome T (COTQF), Bioblast Pharma (ORPN), Neurometrix (NURO), Precipio (PRPO), Argos Therapeutics (ARGS), Alliqua Biomedical (ALQA), RXi Pharmaceuticals (RXII), Amedica (AMDA) and Mateon Therapeutics (MATN).
Who are Aeolus Pharmaceuticals' key executives?
Aeolus Pharmaceuticals' management team includes the folowing people:
- David C. Cavalier, Chairman of the Board, Interim Chief Financial Officer (Age 45)
- John L. McManus, President, Chief Executive Officer (Age 50)
- John M. Clerici, Independent Director (Age 44)
- John M. Farah Jr., Ph.D., Independent Director (Age 62)
- Mitchell D. Kaye J.D., Independent Director (Age 46)
- Amit Kumar Ph.D., Independent Director (Age 53)
- Chris A. Rallis, Independent Director (Age 61)
How do I buy Aeolus Pharmaceuticals stock?
Shares of Aeolus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeolus Pharmaceuticals' stock price today?
One share of Aeolus Pharmaceuticals stock can currently be purchased for approximately $0.04.
How big of a company is Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals has a market capitalization of $7.60 million and generates $2.08 million in revenue each year. The biopharmaceutical company earns $-3,550,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Aeolus Pharmaceuticals employs 4 workers across the globe.
How can I contact Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected].
MarketBeat Community Rating for Aeolus Pharmaceuticals (AOLS)MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings History and Estimates Chart
Aeolus Pharmaceuticals (OTCMKTS AOLS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2017||Q3 2017||($0.01)||$0.01 million||View||N/A|
|5/15/2017||Q2 2017||($0.01)||$0.13 million||View||N/A|
|2/17/2017||Q1 2017||($0.01)||$0.08 million||View||N/A|
|12/21/2016||Q4 2016||($0.01)||$0.55 million||View||N/A|
|8/15/2016||Q3 2016||($0.01)||$0.66 million||View||N/A|
|5/16/2016||Q2 2016||($0.02)||$0.57 million||View||N/A|
|2/16/2016||Q1 2016||($0.01)||$0.31 million||View||N/A|
|8/17/2015||Q3 2015||($0.01)||$0.06 million||View||N/A|
|5/15/2015||Q2 2015||($0.01)||$1.19 million||View||N/A|
|2/13/2015||Q1 2015||($0.01)||$0.93 million||View||N/A|
|8/15/2014||Q3 2014||$0.01||$4.98 million||View||N/A|
|2/14/2014||Q1 2014||($0.01)||$0.79 million||View||N/A|
|8/14/2013||Q3 2013||($0.01)||$0.84 million||View||N/A|
|5/15/2013||Q2 2013||($0.01)||$0.86 million||View||N/A|
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)
No dividend announcements for this company have been tracked by MarketBeat.com
Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 66.60%
Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/6/2013||John L Mcmanus||CEO||Buy||10,000||$0.35||$3,500.00|| |
Aeolus Pharmaceuticals (OTCMKTS AOLS) News Headlines
Aeolus Pharmaceuticals (OTCMKTS:AOLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Income Statement, Balance Sheet and Cash Flow Statement
Aeolus Pharmaceuticals (OTCMKTS AOLS) Stock Chart for Tuesday, February, 20, 2018